Only the triple therapy with prolonged IL-2 demonstrated significant improvement in overall survival, highlighting the rapid progression of the tumour model was challenging our ability to fully explore the real potential of triple therapy (Figure 5c). This evidence concerns the gene IL2 and neoplasm.